Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
None
Analysis of Capillary Retinal and Papillary Vascularization in Patients With Amyotrophic Lateral Sclerosis - CAPISLA

patients are affected in France. The only therapeutic treatment available to date in France is riluzole, which slows the progression of the disease. Amyotrophic Lateral Sclerosis is the first degenerative

primary lateral sclerosis
riluzole
Accepts healthy volunteers
neurological disorder
  • 0 views
  • 14 Oct, 2021
  • 1 location
None
The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.

Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is 3 years. Apart from Riluzole, there is no

primary lateral sclerosis
riluzole
progressive disease
weakness
  • 12 views
  • 20 Jun, 2021
  • 9 locations
None
A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study

Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The mean survival from the time of diagnosis is 2.5 years. Apart from Riluzole, there is no

primary lateral sclerosis
riluzole
progressive disease
  • 0 views
  • 03 Nov, 2021
  • 17 locations
None
iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study

This is a phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of bosutinib to determine the maximum tolerated dose(MTD) and a recommended phase 2 dose (RP2D) of bosutinib for treatment of ALS patients. Also, efficacy will be evaluated exploratory.

  • 0 views
  • 19 Feb, 2021
  • 4 locations
None
Arbaclofen in Children and Adolescents With ASD

AIMS-2-CT-01 is a randomized, double-blind, placebo controlled, study to explore the efficacy, safety and tolerability of Arbaclofen administered to children and adolescents (ages 5-17) for the treatment of social adaptive function in participants with ASD. The effects of Arbaclofen on social function in children and adolescents with ASD will be …

pervasive developmental disorder
seizure
autism
psychotropic drugs
epilepsy
  • 15 views
  • 04 Oct, 2021
  • 7 locations
None
Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients

Amyotrophic lateral sclerosis (ALS) is a disease of an inflammatory nature, which causes progressive muscle weakness associated with cognitive and behavioural disorders. Pathogenically, it is characterised by loss of oxidative control, excitotoxicity due to excess glutamate and intestinal dysbiosis. In the absence of curative treatment, the aim of the study …

primary lateral sclerosis
weakness
  • 13 views
  • 26 Dec, 2021
  • 1 location
None
COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory compromise is common in ALS patients and …

  • 0 views
  • 26 Jan, 2021
  • 1 location
None
Amyotrophic Lateral Sclerosis and the Innate Immune System

Amyotrophic Lateral Sclerosis (ALS) is an aggressive, deadly disease. ALS leads to destruction of the neural pathways which control the conscious movements of the muscles. This destruction leads to muscular dystrophy with increasing difficulties in moving, breathing, swallowing, and speaking. In the last phase of an ALS patient's life it …

primary lateral sclerosis
grave disease
muscular dystrophy
amyotrophic lateral sclerosis
respiratory therapy
  • 82 views
  • 21 Jan, 2021
  • 7 locations